Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volume.
The authors describe the feasibility of dynamic MRI using a novel superparamagnetic iron oxide contrast agent. Resovist was injected as a bolus at doses of 4, 8, and 16 mumol Fe/kg bodyweight in three consented patients participating in a Phase 2 clinical multicenter trial for hepatic MRI. Dynamic images of the brain were obtained with a conventional FLASH sequence. Results were analyzed by evaluation of dynamic images, cerebral blood volume maps, and normalized signal intensity time curves. Resovist enabled rapid injections and a dose-dependent strong reduction in gray and white matter signal intensity. The small injection volume and good tolerability may enable Resovist to serve as a perfusion agent. Dedicated clinical trials are warranted to assess the potentials of Resovist for perfusion MRI and fMRI.
Institute of Clinical Radiology, Westfalian Wilhelms-University Muenster, FRG.
P
P
Reimer
G
G
Schuierer
T
T
Balzer
P E
PE
Peters
D001810:Blood Volume; D002560:Cerebrovascular Circulation; D003287:Contrast Media; D003911:Dextrans; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D052203:Ferrosoferric Oxide; D019786:Gadolinium DTPA; D006801:Humans; D007501:Iron; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D008536:Meglumine; D009942:Organometallic Compounds; D010087:Oxides; D004369:Pentetic Acid / Q000031:analogs & derivatives
D003287:Contrast Media; D003911:Dextrans; D004338:Drug Combinations; D058185:Magnetite Nanoparticles; D009942:Organometallic Compounds; D010087:Oxides; D008536:Meglumine; D004369:Pentetic Acid; D007501:Iron; C065507:ferumoxides; D019786:Gadolinium DTPA; D052203:Ferrosoferric Oxide